MedTrace Logo

The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol

NCT05742724 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-11-20

No results posted yet for this study

Summary

POT-GFR-PK is a single dose pharmacokinetic study oral tetrahydrocannabinol (THC) and cannabidiol (CBD) in healthy adult controls and individuals with chronic kidney disease including those treated with in-center hemodialysis.

Conditions

  • Cannabis
  • Chronic Kidney Diseases
  • Dialysis

Interventions

DRUG

Tetrahydrocannabinol-Cannabidiol Combination

Oral THC 0.1mg/kg and CBD 2.5mg/kg

Sponsors & Collaborators

Principal Investigators

  • Michael Walsh, MD, PhD · McMaster University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-11
Primary Completion
2024-02-16
Completion
2025-03-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05742724 on ClinicalTrials.gov